Pfizer has released details of its new consolidated pipeline following its merger with Wyeth, announcing new priority research areas, and the abandonment of 100 less promising projects.
The company says it wants to be the market leader in six areas of research and as well as in the broader fields of vaccines and biologics.
The six key “Invest to Win” therapy areas are: oncology, pain, inflammation, Alzheimer’s disease, psychoses and diabetes.
The company’s pipeline now includes a total of six vaccines and 27 biologics, up from one vaccine and 16 biologics from the previous pipeline update in March 2009.
The company has cut a total of 100 existing projects create its new ‘prioritised portfolio’ with approximately 70% of Pfizer’s research projects and 75% of the late-stage portfolio focused on these areas.More
No comments:
Post a Comment